CN113476554A - 益气补血且提高免疫力的三味胎盘膏及其制备方法 - Google Patents
益气补血且提高免疫力的三味胎盘膏及其制备方法 Download PDFInfo
- Publication number
- CN113476554A CN113476554A CN202110881011.5A CN202110881011A CN113476554A CN 113476554 A CN113476554 A CN 113476554A CN 202110881011 A CN202110881011 A CN 202110881011A CN 113476554 A CN113476554 A CN 113476554A
- Authority
- CN
- China
- Prior art keywords
- placenta
- preparing
- paste
- sheep
- sheep placenta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002826 placenta Anatomy 0.000 title claims abstract description 132
- 239000000796 flavoring agent Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 210000004369 blood Anatomy 0.000 title abstract description 45
- 239000008280 blood Substances 0.000 title abstract description 45
- 230000036039 immunity Effects 0.000 title abstract description 26
- 241001494479 Pecora Species 0.000 claims abstract description 75
- 238000002156 mixing Methods 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 27
- 239000004615 ingredient Substances 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000000047 product Substances 0.000 claims abstract description 19
- 235000006533 astragalus Nutrition 0.000 claims abstract description 14
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 13
- 239000000413 hydrolysate Substances 0.000 claims abstract description 12
- 241001061264 Astragalus Species 0.000 claims abstract description 8
- 210000004233 talus Anatomy 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002002 slurry Substances 0.000 claims description 14
- 230000009849 deactivation Effects 0.000 claims description 13
- 230000003169 placental effect Effects 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 10
- 238000000855 fermentation Methods 0.000 claims description 10
- 230000004151 fermentation Effects 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 241000045403 Astragalus propinquus Species 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 claims 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims 2
- 238000000265 homogenisation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 230000007812 deficiency Effects 0.000 abstract description 14
- 238000005728 strengthening Methods 0.000 abstract description 14
- 238000002512 chemotherapy Methods 0.000 abstract description 7
- 208000000044 Amnesia Diseases 0.000 abstract description 6
- 208000031091 Amnestic disease Diseases 0.000 abstract description 6
- 208000017667 Chronic Disease Diseases 0.000 abstract description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 6
- 230000006986 amnesia Effects 0.000 abstract description 6
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 6
- 206010022437 insomnia Diseases 0.000 abstract description 6
- 201000002364 leukopenia Diseases 0.000 abstract description 6
- 231100001022 leukopenia Toxicity 0.000 abstract description 6
- 238000001959 radiotherapy Methods 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 5
- 238000010923 batch production Methods 0.000 abstract description 5
- 208000026278 immune system disease Diseases 0.000 abstract description 5
- 208000027905 limb weakness Diseases 0.000 abstract description 5
- 231100000861 limb weakness Toxicity 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 29
- 238000012360 testing method Methods 0.000 description 25
- 230000006870 function Effects 0.000 description 23
- 210000000952 spleen Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000036737 immune function Effects 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 210000000683 abdominal cavity Anatomy 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000010977 jade Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000009571 yupingfeng Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010026820 marasmus Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种益气补血且提高免疫力的三味胎盘膏及其制备方法,一种益气补血且提高免疫力的三味胎盘膏由如下重量份的组分组成:羊胎盘34‑36份,黄精1.8‑2.2份,黄芪1.8‑2.2份;其制备方法包括:(1)准备原料;(2)羊胎盘预处理;(3)制备羊胎盘酶解液;(4)煎制药液;(5)混合;(6)制得三味胎盘膏成品。本发明提供的三味胎盘膏具有良好的扶正固本,益气养血,提高免疫力的功效,适用于体质虚弱,久病,慢性肾脏疾病,术后、产后引起的气血双亏症,症见面色苍白或萎黄,气短懒言,肢体无力酸痛,失眠健忘及放化疗后白细胞减少,免疫功能紊乱等;本发明提供的三味胎盘膏的制备方法工艺过程简单,方便批量生产。
Description
技术领域:
本发明专利涉及一种三味胎盘膏及其制备方法,具体涉及一种益气补血且提高免疫力的三味胎盘膏及其制备方法。
背景技术:
近年来随着免疫学的发展,现代研究表明许多疾病与免疫功能低下密切相关,比如亚健康、癌症等疾病。因此寻求一种有效的免疫增强剂迫在眉睫。中药凭借其简、便、验、廉以及副作用小等优势已经得到广大群众的认可,其中羊胎盘的提取液中富含小分子多肽、核酸、酶、氨基酸、生长因子及胶原蛋白等多种活性物质,具有提高机体免疫力、增强缺氧耐受能力及延缓衰老等作用;目前市场大多售卖单独以羊胎盘粉制作的保健品,但是其对于提高人体的免疫力,以及对人体的益气补血的效果不佳,因此研制开发一种效果显著的具有益气补血、提高免疫力功能的产品势在必行。
发明内容:
有鉴于此,本发明的第一个目的在于提供一种益气补血且提高免疫力的三味胎盘膏。
本发明的第二个目的在于提供一种益气补血且提高免疫力的三味胎盘膏的制备方法。
本发明的第一个目的在于提供一种益气补血且提高免疫力的三味胎盘膏,其由如下重量份的组分组成:羊胎盘34-36份,黄精1.8-2.2份,黄芪1.8-2.2份。
羊胎盘的性味与归经:甘,温,归心、肺、脾及肾经。功能与主治:温补肾阳,益气养血。用于肾虚羸瘦,骨蒸盗汗,阳痿遗精,咳嗽气喘,食少气短等。
黄精的性味与归经:甘,平,归脾、肺、肾经。功能与主治:补气养阴,健脾,润肺,益肾。用于脾胃气虚,体倦乏力,胃阴不足,口干食少,肺虚燥咳,劳嗽咳血,精血不足,腰膝酸软,须发早白,内热消渴。
黄芪的性味与归经:甘,微温,归肺、脾经。功能与主治:补气升阳,固表止汗,利水消肿,生津养血,行滞通痹,托毒排脓,敛疮生肌。用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,气虚水肿,内热消渴,血虚萎黄,半身不遂,痹痛麻木,痈疽难溃,久溃不敛。
本发明三味胎盘膏以“扶正祛邪”蒙医理论为依据,在滋补、强身、提高免疫、“未病”治疗等方面疗效确切。组方中,“君药”羊胎盘具有温肾补精、益气养血、解毒的功能;“臣药”黄精具滋补、强身、燥“协日乌素”的功能;黄芪具清热、止血、愈合伤口、补气升阳的功能;三者协同配合,扶正固本,具有益气养血之功效。故将功能与主治确定为:扶正固本,益气养血,适用于体质虚弱,久病,慢性肾脏疾病,术后、产后引起的气血双亏症,症见面色苍白或萎黄,气短懒言,肢体无力酸痛,失眠健忘及放化疗后白细胞减少,免疫功能紊乱等。
本发明的第二个目的在于提供一种益气补血且提高免疫力的三味胎盘膏的制备方法,其包括以下步骤:(1)准备原料;(2)羊胎盘预处理;(3)制备羊胎盘酶解液;(4)煎制药液;(5)混合;(6)制得三味胎盘膏成品;
(1)准备原料:按重量比例分别称取羊胎盘、黄精和黄芪;
(2)羊胎盘预处理:将步骤(1)中新鲜羊胎盘通过清水进行清洗,然后进行组织匀浆,得到羊胎盘浆;
(3)制备羊胎盘酶解液:将步骤(2)中所述羊胎盘浆与纯化水按照质量比1:0.8-1.2置于发酵罐中,加热至85-95℃,保持10-15min,接着在30min内降温至50-60℃后恒温,然后向所述发酵罐中加入蛋白酶,进行酶解,最后经过灭酶,得到羊胎盘酶解液;
(4)煎制药液:将步骤(1)中的所述黄精和所述黄芪原料混合进行煎煮,共煎煮2次,每次煎煮1.8-2.2h,每次加入的水量为原料的14-16倍重量,最后合并两次煎煮、过滤后的药液;
(5)混合:将步骤(3)中的所述羊胎盘酶解液和步骤(4)中的药液混合均匀,得到混合药液;
(6)制得三味胎盘膏成品:将所述混合药液离心,取离心液,加入红糖混匀,然后浓缩至膏状,分装,即得三味胎盘膏成品。
进一步的,在步骤(3)中,每1kg所述羊胎盘浆中加入10-13ml的所述蛋白酶。
进一步的,步骤(3)中的所述酶解的温度为50-60℃,所述酶解的时间为4-4.5h。
进一步的,步骤(3)中的所述灭酶的温度为85-95℃,所述灭酶的时间为10-15min。
进一步的,步骤(3)中,离心分离的转速为13000-15000rpm,离心分离的时间为120-150min。
本发明的优点:
本发明提供的三味胎盘膏具有良好的扶正固本,益气养血,提高免疫力的功效,适用于体质虚弱,久病,慢性肾脏疾病,术后、产后引起的气血双亏症,症见面色苍白或萎黄,气短懒言,肢体无力酸痛,失眠健忘及放化疗后白细胞减少,免疫功能紊乱等;本发明提供的三味胎盘膏的制备方法工艺过程简单,方便批量生产。
附图说明:
图1为各测试组小鼠体重随时间变化情况图;
图2为各测试组小鼠脾脏指数对比柱状图;
图3为各测试组小鼠胸腺指数对比柱状图;
图4为各测试组小鼠WBC对比柱状图;
图5为各测试组小鼠Lymph对比柱状图;
图6为各测试组小鼠IgA对比柱状图;
图7为各测试组小鼠IgG对比柱状图;
图8为各测试组小鼠IgM对比柱状图;
图9为各测试组小鼠淋转24h对比柱状图;
图10为各测试组小鼠淋转48h对比柱状图;
图11为各测试组小鼠溶血空斑数对比柱状图;
图12为各测试组小鼠吞噬率对比柱状图;
图13为各测试组小鼠吞噬指数对比柱状图;
图14为各测试组小鼠NK细胞活性对比柱状图。
具体实施方式:
下面通过实施例对本发明作进一步的详细说明。
实施例1:一种益气补血且提高免疫力的三味胎盘膏,其由如下重量份的组分组成:羊胎盘35份,黄精2份,黄芪2份。
本实施例提供的三味胎盘膏中羊胎盘为君药具有温肾补精、益气养血、解毒的功能;黄精和黄芪为臣药,黄精具滋补、强身、燥“协日乌素”的功能;黄芪具清热、止血、愈合伤口、补气升阳的功能,三者协同配合具有扶正固本,具有益气养血之功效。
本实施例提供的三味胎盘膏具有良好的扶正固本,益气养血,提高免疫力的功能,适用于体质虚弱,久病,慢性肾脏疾病,术后、产后引起的气血双亏症,症见面色苍白或萎黄,气短懒言,肢体无力酸痛,失眠健忘及放化疗后白细胞减少,免疫功能紊乱等。
实施例2:实施例1所述的一种益气补血且提高免疫力的三味胎盘膏的制备方法,其包括以下步骤:(1)准备原料;(2)羊胎盘预处理;(3)制备羊胎盘酶解液;(4)煎制药液;(5)混合;(6)制得三味胎盘膏成品;
(1)准备原料:按重量比例分别称取新鲜羊胎盘、黄精和黄芪;
(2)羊胎盘预处理:将步骤(1)中新鲜羊胎盘通过清水进行清洗,然后进行组织匀浆,得到羊胎盘浆;
(3)制备羊胎盘酶解液:将步骤(2)中所述羊胎盘浆与纯化水按照质量比1:1置于发酵罐中,加热至90℃,保持10min,接着在30min内降温至55℃后恒温,然后向所述发酵罐中加入蛋白酶,进行酶解,最后经过灭酶,得到羊胎盘酶解液;每1kg所述羊胎盘浆中加入10ml的所述蛋白酶;酶解的温度为55℃,酶解的时间为4h;灭酶的温度为90℃,灭酶的时间为10min。
(4)煎制药液:将步骤(1)中的所述黄精和所述黄芪原料混合进行煎煮,共煎煮2次,每次煎煮2h,每次加入的水量为原料的15倍重量,最后合并两次煎煮、过滤后的药液;
(5)混合:将步骤(3)中的所述羊胎盘酶解液和步骤(4)中的药液混合均匀,得到混合药液;
(6)制得三味胎盘膏成品:将所述混合药液离心,取离心液,加入红糖混匀,然后浓缩至膏状,分装,即得三味胎盘膏成品。其中,离心分离的转速为14000rpm,离心分离的时间为135min。
本发明提供的三味胎盘膏的制备方法工艺过程简单,方便批量生产。
实施例3:一种益气补血且提高免疫力的三味胎盘膏,其由如下重量份的组分组成:羊胎盘34份,黄精1.8份和黄芪1.8份。
本实施例提供的三味胎盘膏中羊胎盘为君药具有温肾补精、益气养血、解毒的功能;黄精和黄芪为臣药,黄精具滋补、强身、燥“协日乌素”的功能;黄芪具清热、止血、愈合伤口、补气升阳的功能,三者协同配合具有扶正固本,具有益气养血之功效。
本实施例提供的三味胎盘膏具有良好的扶正固本,益气养血,提高免疫力的功能,适用于体质虚弱,久病,慢性肾脏疾病,术后、产后引起的气血双亏症,症见面色苍白或萎黄,气短懒言,肢体无力酸痛,失眠健忘及放化疗后白细胞减少,免疫功能紊乱等。
实施例4:实施例3所述的一种益气补血且提高免疫力的三味胎盘膏的制备方法,其包括以下步骤:(1)准备原料;(2)羊胎盘预处理;(3)制备羊胎盘酶解液;(4)煎制药液;(5)混合;(6)制得三味胎盘膏成品;
(1)准备原料:按重量比例分别称取新鲜羊胎盘、黄精和黄芪;
(2)羊胎盘预处理:将步骤(1)中新鲜羊胎盘通过清水进行清洗,然后进行组织匀浆,得到羊胎盘浆;
(3)制备羊胎盘酶解液:将步骤(2)中所述羊胎盘浆与纯化水按照质量比1:1.2置于发酵罐中,加热至90℃,保持10min,接着在30min内降温至50℃后恒温,然后向所述发酵罐中加入蛋白酶,进行酶解,最后经过灭酶,得到羊胎盘酶解液;每1kg所述羊胎盘浆中加入13ml的所述蛋白酶;酶解的温度为50℃,酶解的时间为4.5h;灭酶的温度为95℃,灭酶的时间为10min。
(4)煎制药液:将步骤(1)中的所述黄精和所述黄芪原料混合进行煎煮,共煎煮2次,每次煎煮2.2h,每次加入的水量为原料的16倍重量,最后合并两次煎煮、过滤后的药液;
(5)混合:将步骤(3)中的所述羊胎盘酶解液和步骤(4)中的药液混合均匀,得到混合药液;
(6)制得三味胎盘膏成品:将所述混合药液离心,取离心液,加入红糖混匀,然后浓缩至膏状,分装,即得三味胎盘膏成品。其中,离心分离的转速为15000rpm,离心分离的时间为120min。
本发明提供的三味胎盘膏的制备方法工艺过程简单,方便批量生产。
实施例5:一种益气补血且提高免疫力的三味胎盘膏,其由如下重量份的组分组成:羊胎盘36份,黄精2.2份,黄芪2.2份。
本实施例提供的三味胎盘膏中羊胎盘为君药具有温肾补精、益气养血、解毒的功能;黄精和黄芪为臣药,黄精具滋补、强身、燥“协日乌素”的功能;黄芪具清热、止血、愈合伤口、补气升阳的功能,三者协同配合具有扶正固本,具有益气养血之功效。
本实施例提供的三味胎盘膏具有良好的扶正固本,益气养血,提高免疫力的功能,适用于体质虚弱,久病,慢性肾脏疾病,术后、产后引起的气血双亏症,症见面色苍白或萎黄,气短懒言,肢体无力酸痛,失眠健忘及放化疗后白细胞减少,免疫功能紊乱等。
实施例6:实施例5所述的一种益气补血且提高免疫力的三味胎盘膏的制备方法,其包括以下步骤:(1)准备原料;(2)羊胎盘预处理;(3)制备羊胎盘酶解液;(4)煎制药液;(5)混合;(6)制得三味胎盘膏成品;
(1)准备原料:按重量比例分别称取新鲜羊胎盘、黄精和黄芪;
(2)羊胎盘预处理:将步骤(1)中新鲜羊胎盘通过清水进行清洗,然后进行组织匀浆,得到羊胎盘浆;
(3)制备羊胎盘酶解液:将步骤(2)中所述羊胎盘浆与纯化水按照质量比1:0.8置于发酵罐中,加热至85℃,保持15min,接着在30min内降温至60℃后恒温,然后向所述发酵罐中加入蛋白酶,进行酶解,最后经过灭酶,得到羊胎盘酶解液;每1kg所述羊胎盘浆中加入10ml的所述蛋白酶;酶解的温度为60℃,酶解的时间为4h;灭酶的温度为85℃,灭酶的时间为15min。
(4)煎制药液:将步骤(1)中的所述黄精和所述黄芪原料混合进行煎煮,共煎煮2次,每次煎煮1.8h,每次加入的水量为原料的14倍重量,最后合并两次煎煮、过滤后的药液;
(5)混合:将步骤(3)中的所述羊胎盘酶解液和步骤(4)中的药液混合均匀,得到混合药液;
(6)制得三味胎盘膏成品:将所述混合药液离心,取离心液,加入红糖混匀,然后浓缩至膏状,分装,即得三味胎盘膏成品。其中,离心分离的转速为13000rpm,离心分离的时间为150min。
本发明提供的三味胎盘膏的制备方法工艺过程简单,方便批量生产。
实施例7:药效试验:
一、仪器与材料
1.1仪器
1.2材料
三味胎盘膏(采用本发明实施例2制备的三味胎盘膏)由内蒙古阿拉善盟蒙医医院提供。
环磷酰胺(CAS:6055-19-2)购于上海源叶生物科技有限公司货号:S30563。
羊胎盘酶解液(采用本发明实施例2方法制备)由内蒙古阿拉善盟蒙医医院提供。
玉屏风散购于国药集团广东环球制药有限公司,批号国药准字Z10930036
1.3实验动物
本研究方案经过天津中医药大学动物伦理道德委员会批准进行实验(TCM-LAEC2020046)。本实验中155只ICR雄性小鼠(7-8周,20-22g,SPF级)购买于斯贝福(北京)生物技术有限公司(SCXK(京)2019-0010),并将其饲养于天津中医药大学实验动物中心,室温为22±2℃,湿度为50-60%以及光照/黑暗循环为12/12小时,自由饮用水和食物的环境中。ICR小鼠适应喂养一周,接着用于后续实验实验。
二、研究内容和方法
2.1模型制备
选取雄性ICR小鼠,体重20±2g,适应性喂养一周后,腹腔注射CTX(环磷酰胺)80mg/kg,同时正常组腹腔注射等体积的生理盐水。连续3天建立免疫力低下小鼠模型。
2.2模型验证
15只ICR小鼠分为正常组以及模型组。分为5只正常对照组、10只模型组。模型组小鼠连续3天80mg/kg注射环磷酰胺0.2ml/只,正常对照组腹腔注射等剂量生理盐水。30天后脱颈处死,称量其脾脏、胸腺质量计算脏器指数和运用ELISA试剂盒检测IgA、IgG、IgM等免疫球蛋白检测进行模型验证。通过检测脏器指数、免疫球蛋白说明2.1的方法制备免疫功能低下模型成功。
2.3研究内容
2.3.1动物分组以及给药方式
ICR小鼠雄性140只,体重20±2g,共分为7组,每组20只按照实验分组灌胃给药30天后取材;
A:空白对照组,每日每只灌胃生理盐水0.2ml
B:免疫功能低下模型组,每日每只灌胃生理盐水0.2ml
C:免疫功能低下+三味胎盘膏低剂量组,每日灌胃三味胎盘膏1125mg/kg
D:免疫功能低下+三味胎盘膏中剂量组,每日灌胃三味胎盘膏2250mg/kg
E:免疫功能低下+三味胎盘膏高剂量组,每日灌胃三味胎盘膏4500mg/kg
F:对照一组免疫力低下+羊胎盘酶解液,每日灌胃羊胎盘酶解液4500mg/kg
G:对照二组免疫力低下+玉屏风散,每日玉屏风散0.18g/ml
2.3.2研究内容及研究结果
(1)生活状态的评价:
在整个饲养动物期间观察小鼠精神状态、毛发等变化,每日测定其体重(比较造模前中后的体重变化),研究结果如表1、图1所示,图中:正常组与模型组相比p<0.05,三味胎盘膏低剂量组、中剂量组、高剂量组、对照一组、对照二组与模型组相比p<0.05。
表1:生活状态评价表
(2)脏器指数的测定:
取其胸腺以及脾脏计算其脏器指数,计算相应脏器指数(mg/g)=脏器重量(mg)/体重(g),研究结果如图2、图3所示,图中,####为p<0.0001,###为P<0.001,****为p<0.0001,***为P<0.001。
(3)血常规检测(红细胞、白细胞、血小板检测)
小鼠处死之后取血进行血常规检测。研究结果如图4、图5所示。
(4)免疫球蛋白检测
小鼠处死之后离心取血清运用相关试剂盒进行IgA、IgG、IgM测定。如图6-8所示,图中####为p<0.0001,###为P<0.001,****为p<0.0001,***为P<0.001。
(5)通过CCK-8法检测ConA诱导的小鼠淋巴细胞增殖转化功能对细胞免疫功能进行测定
小鼠处死后,无菌取脾,制备3×106个/m L脾细胞悬液,将细胞悬液分两孔加入96孔培养板中,每孔1mL,一孔加75μL ConA液(75μg/m L),另一孔作为对照,置37℃、5%CO2培养箱中培养24h和48h。采用CCK-8比色法测定光密度,计算脾淋巴细胞增殖能力,结果如图9-10所示。
(6)通过Jerne改良玻片法检测小鼠抗体生成细胞数进行体液免疫功能测定
按照改良玻片法,取羊血,用生理盐水洗涤3次,每次离心(2000r/min)10min,将压积SRBC用生理盐水配成2%(v/v)的细胞悬液,每鼠腹腔注射0.2mL进行免疫。将免疫后4d的小鼠处死,取脾,轻轻撕碎,用Hank’s液制成细胞悬液,200目筛网过滤,洗涤、离心2次,最后将细胞悬浮在5mL Hank’s液中。将表层培养基加热溶解后与等量的pH7.4、2倍浓度的Hank’s液混合,分装小试管,每管0.5mL,再向管内加入用SA液配制的10%SRBC 50μL(v/v)、20μL脾细胞悬液,迅速混匀后倾倒于已刷薄层琼脂糖的玻片上,待琼脂糖凝固后将玻片水平扣放在玻片架上,放入二氧化碳培养箱中温育1.5h,然后用SA液稀释的补体(1:10)加入到玻片凹槽内,继续温育1.5h后计数溶血空斑数。测试结果如图11所示。
(7)通过滴片法检测小鼠腹腔巨噬细胞吞噬鸡红细胞能力进行单核-巨噬细胞功能测定
采用每只小鼠腹腔注射2%(V/V)SRBC 0.2mL。4d后颈椎脱臼处死小鼠,每只腹腔注射加小牛血清的Hank's液4mL,充分洗出腹腔巨噬细胞,收集腹腔洗液至试管内。在试管内加入0.5mL腹腔洗液、0.5mL 1%鸡血红细胞悬液,混匀,吸取0.5mL混合液加入玻片上已晾干的3%琼脂圈内,37℃温育20min,甲醇固定、Gimsa液染色,显微镜观察,计数吞噬率和吞噬指数。测试结果如图12-13所示。
(8)通过乳酸脱氢酶测定法检测NK细胞活性
小鼠处死后,取脾脏制备2.5×107/ml的脾淋巴细胞悬液,用含有0.5%牛血清白蛋白(albumin from bovine serum,BSA)的RPMI-1640培养液重悬作为效应细胞;5×105/mL的YAC-1细胞以含0.5%BSA的RPMI-1640培养液重悬作为靶细胞;向96孔板分别加入100μl的效应细胞和靶细胞(效应细胞∶靶细胞=50:1),对照孔加100μl的靶细胞和100μl含0.5%BSA的RPMI-1640培养液,最大释放孔加100μl的靶细胞和20%NP-40裂解液100μl,置于37℃,5%二氧化碳培养箱中培养4h;然后将96孔培养板以1500r/min离心5min,每孔吸取上清100μL置平底96孔培养板中,同时加入LDH基质液100μL,反应3min,每孔加入1mol/L的HCL 300μL,在酶标仪490nm处测定光密度值(A)。根据公式计算NK细胞活度。测试结果如图14所示。
以上研究结果表明,通过建立免疫功能低下模型,灌胃30天三味胎盘膏(低中高剂量)之后对免疫功能低下模型小鼠进行一般生活评价、脏器指数的测定、血常规检测、免疫球蛋白检测、等指标表明三味胎盘膏对免疫功能低下模型有明显的治疗作用,且效果明显优于F组-羊胎盘酶解液和G组-玉屏风散组;通过CCK-8法检测ConA诱导的小鼠淋巴细胞增殖转化功能证明可提高细胞免疫功能,且中剂量组和高剂量组效果明显优于F组-羊胎盘酶解液和G组-玉屏风散组;通过Jerne改良玻片法检测小鼠抗体生成细胞数证明可提高体液免疫功能,且高剂量组效果明显优于F组-羊胎盘酶解液和G组-玉屏风散组;通过滴片法检测小鼠腹腔巨噬细胞吞噬鸡红细胞能力证明可以提高单核-巨噬细胞功能,且高剂量组效果明显优于F组-羊胎盘酶解液和G组-玉屏风散组;通过乳酸脱氢酶测定法证明可以提高NK细胞活性。三味胎盘膏可显著提高免疫功能低下模型小鼠的非特异性免疫功能和特异性免疫功能,且中剂量组效果明显优于F组-羊胎盘酶解液和G组-玉屏风散组。
实施例8:毒性试验
通过长期毒性试验表明,本发明三味胎盘膏在同性别SD大鼠毒性试验中,高剂量(给药量为折合生药139.2g/kg/d,相当于临床成人用药剂量(1.98g/kg/d)的71倍左右)、中剂量(给药量为折合生药69.6g/kg/d,相当于临床成人用药剂量(1.98g/kg/d)的35倍左右)、低剂量(给药量为折合生药1.98g/kg/d,相当于临床成人用药剂量(1.98g/kg/d)的1倍左右)、辅料组(红糖与水进行混合,质量比例为1:134),与对照组(灌胃等体积的生理盐水)比较,给药高、中、低以及辅料组动物一般状况(整个试验期间各组大鼠灌胃两小时内懒动、后采食正常,粪便颗粒状,无软便、稀便;大鼠毛色光润、无明显脱毛表现;喜动、活动自如,无精神萎靡、嗜睡、烦躁、拱背等异常表现;各组体重及生长曲线无明显差异)、血液血常规指标如白细胞计数(WBC#)、淋巴细胞计数(Lymph#)、单核细胞数(Mon#)等24项指标与空白对照组相比无统计学意义,无明显差异。血清生化指标如丙氨酸转氨酶(ALT)、天门冬氨酸转氨酶(AST)、白蛋白(ALB)等15项指标与空白对照组相比无统计学意义,无明显差异。尿液检测如尿比重、PH、亚硝酸盐、尿糖等11项指标与空白对照组相比无统计学意义,无明显差异。动物体重(连续监测17周)、主要脏器指数(心、肝、脾、肺、肾等12个脏器)与空白对照组无统计学差异,通过病理学检查心、肝、脾、肺、肾等12个脏器未见组织发生病变、细胞坏死、水肿、炎性病变等变化,在毒性试验中高剂量组给药倍数已达到临床用药浓度71倍,上述检测指标均在正常值之内,且与空白对照组无统计学意义,表明本发明“三味胎盘膏”毒性低,适用于临床长期用药。
以上是本发明的优选实施方式,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (6)
1.一种益气补血且提高免疫力的三味胎盘膏,其特征在于,其由如下重量份的组分组成:羊胎盘34-36份,黄精1.8-2.2份,黄芪1.8-2.2份。
2.一种权利要求1所述的三味胎盘膏的制备方法,其特征在于,其包括以下步骤:(1)准备原料;(2)羊胎盘预处理;(3)制备羊胎盘酶解液;(4)煎制药液;(5)混合;(6)制得三味胎盘膏成品;
(1)准备原料:按重量比例分别称取羊胎盘、黄精和黄芪;
(2)羊胎盘预处理:将步骤(1)中羊胎盘通过清水进行清洗,然后进行组织匀浆,得到羊胎盘浆;
(3)制备羊胎盘酶解液:将步骤(2)中所述羊胎盘浆与纯化水按照质量比1:0.8-1.2置于发酵罐中,加热至85-95℃,保持10-15min,接着在30min内降温至50-60℃后恒温,然后向所述发酵罐中加入蛋白酶,进行酶解,最后经过灭酶,得到羊胎盘酶解液;
(4)煎制药液:将步骤(1)中的所述黄精和所述黄芪原料混合进行煎煮,共煎煮2次,每次煎煮1.8-2.2h,每次加入的水量为原料的14-16倍重量,最后合并两次煎煮、过滤后的药液;
(5)混合:将步骤(3)中的所述羊胎盘酶解液和步骤(4)中的药液混合均匀,得到混合药液;
(6)制得三味胎盘膏成品:将所述混合药液离心,取离心液,加入红糖混匀,然后浓缩至膏状,分装,即得三味胎盘膏成品。
3.根据权利要求2所述的三味胎盘膏的制备方法,其特征在于,在步骤(3)中,每1kg所述羊胎盘浆中加入10-13ml的所述蛋白酶。
4.根据权利要求2所述的三味胎盘膏的制备方法,其特征在于,步骤(3)中的所述酶解的温度为50-60℃,所述酶解的时间为4-4.5h。
5.根据权利要求2所述的三味胎盘膏的制备方法,其特征在于,步骤(3)中的所述灭酶的温度为85-95℃,所述灭酶的时间为10-15min。
6.根据权利要求2所述的三味胎盘膏的制备方法,其特征在于,步骤(3)中,离心分离的转速为13000-15000rpm,离心分离时间为120-150min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110881011.5A CN113476554A (zh) | 2021-08-02 | 2021-08-02 | 益气补血且提高免疫力的三味胎盘膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110881011.5A CN113476554A (zh) | 2021-08-02 | 2021-08-02 | 益气补血且提高免疫力的三味胎盘膏及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113476554A true CN113476554A (zh) | 2021-10-08 |
Family
ID=77944007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110881011.5A Pending CN113476554A (zh) | 2021-08-02 | 2021-08-02 | 益气补血且提高免疫力的三味胎盘膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113476554A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114886925A (zh) * | 2022-05-25 | 2022-08-12 | 兰州大学 | 羊胎盘提取物在制备预防或治疗癌症恶病质药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102895515A (zh) * | 2011-06-29 | 2013-01-30 | 上海中医药大学附属龙华医院 | 一种升高白细胞的中药组合物及其制备工艺和应用 |
CN103330048A (zh) * | 2013-07-19 | 2013-10-02 | 内蒙古迦妮生物科技开发有限公司 | 一种羊胎盘多肽粉的制备方法及其可溶性颗粒的制备方法 |
-
2021
- 2021-08-02 CN CN202110881011.5A patent/CN113476554A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102895515A (zh) * | 2011-06-29 | 2013-01-30 | 上海中医药大学附属龙华医院 | 一种升高白细胞的中药组合物及其制备工艺和应用 |
CN103330048A (zh) * | 2013-07-19 | 2013-10-02 | 内蒙古迦妮生物科技开发有限公司 | 一种羊胎盘多肽粉的制备方法及其可溶性颗粒的制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114886925A (zh) * | 2022-05-25 | 2022-08-12 | 兰州大学 | 羊胎盘提取物在制备预防或治疗癌症恶病质药物中的应用 |
CN114886925B (zh) * | 2022-05-25 | 2023-10-13 | 兰州大学 | 羊胎盘提取物在制备预防或治疗癌症恶病质药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10813961B2 (en) | Powder formulation having a function of enhancing immunity and method for preparing the same | |
CN112569305A (zh) | 一种提高免疫力的香菇复合多糖组合物及其制备方法 | |
CN102626468B (zh) | 一种治疗乙肝的中药组合物及其制备方法和应用 | |
CN102048902B (zh) | 一种治疗肝炎的中药组合物、提取物及制备方法、应用和剂型 | |
CN108813610B (zh) | 一种用于提高免疫力的雪莲组合物及其应用 | |
CN113476554A (zh) | 益气补血且提高免疫力的三味胎盘膏及其制备方法 | |
CN116785344A (zh) | 具有调节免疫功能的黄芪扶正茶及其制备方法 | |
CN117089580A (zh) | 干酪乳杆菌sf-l-12发酵物及其制备工艺、应用 | |
CN104857435A (zh) | 一种具有抗肿瘤活性的中药复方组合物及其制备方法和应用 | |
CN113855764B (zh) | 用于提高机体免疫力的中药复方制剂 | |
CN101843876B (zh) | 一种预防顺铂所致肾细胞凋亡及贫血的中药组合物及其制备方法 | |
CN116211999A (zh) | 一种含脾肽增强免疫力的配方及原料制备方法 | |
CN106728387B (zh) | 一种具有促进免疫功能的复方药物及其制备方法 | |
CN104524292A (zh) | 一种中药制剂用于制备治疗肥胖药物中的用途 | |
CN112891492A (zh) | 一种中药首乌益髓组合物及其胶囊和膏剂的制备方法 | |
CN103169838B (zh) | 一种治疗乙型肝炎的药物 | |
CN104547738A (zh) | 一种治疗肥胖的中药制剂及其制备方法 | |
CN114949114B (zh) | 一种有助于增强免疫力的含沉香中药组合物及其制备方法、制剂与应用 | |
CN109620911B (zh) | 一种具有改善化疗后中性粒细胞减少症的中药组合物及其用途 | |
CN111346172B (zh) | 一种提高免疫力的药物组合物 | |
CN103055036A (zh) | 一种治疗白细胞减少症的药剂的制备方法 | |
CN114470144B (zh) | 用于抑制前列腺纤维化的前列消汤及其制备方法 | |
CN103271992B (zh) | 一种用于提高免疫力的药物组合物 | |
CN1101559A (zh) | 一种中药抗癌口服液及其制备方法 | |
CN112890195A (zh) | 一种增强免疫力功能中药保健品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211008 |
|
RJ01 | Rejection of invention patent application after publication |